CN110354245A - 一种用于治疗痛风的复合制品及其制备方法 - Google Patents
一种用于治疗痛风的复合制品及其制备方法 Download PDFInfo
- Publication number
- CN110354245A CN110354245A CN201910641415.XA CN201910641415A CN110354245A CN 110354245 A CN110354245 A CN 110354245A CN 201910641415 A CN201910641415 A CN 201910641415A CN 110354245 A CN110354245 A CN 110354245A
- Authority
- CN
- China
- Prior art keywords
- composite article
- gout
- compound
- giant salamander
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 54
- 239000002131 composite material Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
- 241000157862 Dicamptodontidae Species 0.000 claims abstract description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 27
- 239000012530 fluid Substances 0.000 claims abstract description 20
- 210000003038 endothelium Anatomy 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 210000001519 tissue Anatomy 0.000 claims abstract description 16
- 241000411851 herbal medicine Species 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 6
- 239000004365 Protease Substances 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 10
- 240000008042 Zea mays Species 0.000 claims description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 10
- 235000005822 corn Nutrition 0.000 claims description 10
- 235000013717 Houttuynia Nutrition 0.000 claims description 9
- 240000000691 Houttuynia cordata Species 0.000 claims description 9
- 244000046146 Pueraria lobata Species 0.000 claims description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 9
- 240000003915 Lophatherum gracile Species 0.000 claims description 8
- 230000029087 digestion Effects 0.000 claims description 6
- 239000008361 herbal raw material Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000004677 Nylon Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001778 nylon Polymers 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 2
- 244000088415 Raphanus sativus Species 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 240000002014 Phyllostachys nigra var. henonis Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000007787 solid Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 241000269333 Caudata Species 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 238000001694 spray drying Methods 0.000 abstract description 2
- 235000021056 liquid food Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 102000035195 Peptidases Human genes 0.000 description 12
- 235000019419 proteases Nutrition 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 102000003792 Metallothionein Human genes 0.000 description 7
- 108090000157 Metallothionein Proteins 0.000 description 7
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 6
- 241000220259 Raphanus Species 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 102000004400 Aminopeptidases Human genes 0.000 description 3
- 108090000915 Aminopeptidases Proteins 0.000 description 3
- 102000005367 Carboxypeptidases Human genes 0.000 description 3
- 108010006303 Carboxypeptidases Proteins 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 2
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002310 elbow joint Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- -1 Febustat piece Chemical compound 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000745390 Lophatherum Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007460 surgical drainage Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于生物保健食品和医药品制备技术领域,具体为一种用于治疗痛风的复合制品及其制备方法。该复合制品是以大鲵全鲵组织和鸡内金经生物酶解,膜过滤获得的复合蛋白多肽液,并与当归等中草药熬制的药液配伍,添加辅料制备成液体保健食品和药品;将复合蛋白多肽液与当归等中草药熬制的药液配伍混合,经冷冻或低温喷雾干燥获得复合原粉,根据剂型、剂量加入辅料制成不同剂型的固体保健食品和药品。该复合制品克服了现有药品和手术治疗痛风治标不治本的诸多弊端。
Description
技术领域
本发明属于生物保健食品和医药品制备技术领域,具体为一种用于治疗痛风的复合制品及其制备方法。
背景技术
痛风是全球增长率最快的慢性病之一,已成为我国仅次于糖尿病的第二大代谢类疾病,患者已超过8000万人,并还在以9.7%的年增长率迅速增加,且趋于年轻化。此病发作时疼痛难忍,苦不堪言,轻者影响正常工作和生活,严重时可造成人体关节沉积大量的结石致使关节变形,肾功能损害、瘫痪、甚至死亡。给患者的身心、家庭和社会带来严重的影响。
目前,治疗痛风的药物主要有秋水仙碱、非布司他片、别嘌醇、苯溴马隆和一些中草药等。我们通过相关资料查阅和对许多痛风患者包括医生、教师、领导和其他社会人士的深度调研,其结果是:一是上述药物在治疗痛风中虽然迅速有效,解决了临时疼痛和红肿,但那只是治了标,因为人体的痛风结石还在继续沉积增大,故未能达到治本;二是上述药物若长期服用将会对人体的肝肾有不同程度的副作用;三是在治疗人体关节已形成的积液和痛风结石时,目前主要采用手术抽取或手术摘除。由于人体经络特别是手指经络复杂而细小,因此,在手术中经络的损伤几率特别大,一旦经络被损伤坏死,其尿液中的晶体物质和非晶体物质便无法通过损伤的经络而沉积于此,最后形成结石无法根治。
发明内容
本发明的目的是针对上述痛风治疗过程中存在的治标不治本等问题,提供一种用于治疗痛风的复合制品及其制备方法。该复合制品是以大鲵全鲵组织和鸡内金经酶解分离的复合蛋白多肽为主要原料,在配伍少量中草药熬制的药液或该药液喷雾干燥的复合原粉混合而成。该复合制品能够有效解决上述药品和手术治疗痛风中的弊端,达到标本兼治,且该复合制品的制备方法简单科学。
为了实现上述发明目的,本发明采用的技术方案如下:
一种用于治疗痛风的复合制品,该复合制品中含有大鲵多肽和鸡内金酶解物。
一种用于治疗痛风的复合制品,包括复合蛋白多肽和中药组合物;其中所述的复合蛋白多肽由大鲵全体组织、鸡内金和复合蛋白酶为主要原料制备而成;中药组合物由当归、枸杞、葛根、莱菔子、淡竹叶、玉米须和鱼腥草制备而成;复合蛋白多肽和中药组合物的50-180:20-100。
所述中药组合物中各原料的重量份为:当归1-9份,枸杞1-10份,葛根1-12份,莱菔子1-15份,淡竹叶1-6份,玉米须1-10份,鱼腥草1-3份。
作为优选,采用以上配方制备用于治疗痛风液剂的方法,包括以下步骤:
⑴、大鲵全体组织与鸡内金混合,再加入复合蛋白酶经酶解分离获得的复合蛋白多肽原液备用;
大鲵全体组织:将活大鲵停食数天使其排空肠道,再宰杀去胆囊,得大鲵全体组织。
作为优选,步骤(1)的具体步骤为:
(1.1)将大鲵全体组织36kg和鸡内金5kg加纯净水36L进行蒸煮,蒸煮温度为120℃,压力为0.15MPa,蒸煮时间为0.5h。
(1.2)向蒸煮后的料液中加入纯净水108L,当温度降至50℃,然后加入复合蛋白酶1.2kg,然后将料液温度始终控制在50℃并保持5—6h,期间保持均速搅动,最后获得酶解液。
所述复合蛋白酶由中性蛋白酶、木瓜蛋白酶和风味蛋白酶组成,所述风味蛋白酶由氨肽酶和羧肽酶组成。所述中性蛋白酶用量为大鲵全体组织质量的0.5%-1.5%,木瓜蛋白酶用量为大鲵全体组织质量的0.6%-2.0%;所述风味蛋白酶由氨肽酶和羧肽酶以质量比3-5:1组成,风味蛋白酶用量为大鲵全体组织质量的0.3-1.0%。
(1.3)将步骤(1.2)中得到的酶解液进行离心分离,离心机的转速为15000转/min;得到的离心液经20000Da超滤膜过滤,得分子量≤20000Da的蛋白多肽原液125L。
⑵、按比例称取当归、枸杞、葛根、莱菔子、鱼腥草、淡竹叶和玉米须,然后加水进行熬制,再将熬制的药液用500目尼龙筛布过滤,最后浓缩成中草药原液备用。
作为优选,步骤(2)的具体步骤为:
(2.1)将称取到的中草药原料当归5kg、枸杞5kg、葛根6kg、莱菔子8kg、鱼腥草2kg、淡竹叶3kg和玉米须5kg混合在一起后加水浸泡1h,水与中草药原料的质量比为4:1,然后用旺火将药液熬至沸腾,然后小火再熬制1.5h即可;
(2.2)将熬制好的药液温度降至30℃,用500目尼龙筛布过滤获得药液,然后在将药液放入浴锅内浓缩得中药组合物原液50L。
⑶、将备用的复合蛋白多肽原液、中草药原液、柠檬酸、黄原胶、三氯蔗糖和山梨酸钾进行胶体磨混合即得。
作为优选,步骤(3)的具体步骤为:将备用的复合蛋白多肽原液125L和中草药原液50L混合,再向混合液中加入柠檬酸1400g、黄原胶260g、三氯蔗糖62g和山梨酸钾75进行胶体磨混合即得。
药剂的制备方法还包括步骤(4)、将混合好的药剂进行灌装,灌装剂量为每支10mL至60mL,灌装好的产品进行巴氏灭菌,然后烘干表面水分,然后贴标;
(5)、将上述贴标后的产品进行卫生检测,合格后,装盒装箱入库。
本液剂中,蛋白质含量≥2.11g/100mL,脂肪≥0.1g/100mL,肽≥1.9g/100mL,有微弱的大鲵腥味。每人每天服用量为10—60mL,早晚饭前服用。
本申请中所述的用于治疗痛风的复合制品也可以制备成固体制品,制备固体制品的辅材根据剂型、剂量确定选用材料和添加量,固体复合制品每人每天建议服用量为0.583g—1.749g。
大鲵须采用全鲵(包括大鲵的卫生指标符合国家相关标准,养殖人需取得水生野生动物经营利用许可证)。
大鲵生存距今已有3亿5千万年,最长寿命200—300年。除已知大鲵肝脏中富含大量的金属硫蛋白,骨为软骨并富含硒等元素和肌肉蛋白质中必须氨基酸含量较高外,它体内或某个组织还有现代科学未发现的某种物质。本发明人发现,这些物质或许就是治疗痛风的主要物质、或许这些物质与上述金属硫蛋白等物质的相互协同才能完成对痛风的治疗。而已知大鲵肝脏中富含金属硫蛋白,而它的尾部却不含金属硫蛋白,而是含有丰富的脂肪,同理,若是诸如肌肉或其它某个组织的缺失,而这个缺失组织中正好含有治疗痛风所需要的某种物质,如果这种必须的物质一旦缺失,其后果就不能达到治疗痛风之目的。因此,采用大鲵的全部组织来获得大鲵蛋白多肽是必要的。
鸡内金—健胃消食,涩精止遗,通淋化石。
当归—补血和血,润燥滑肠。
枸杞—益精明目,滋补肝肾。
葛根—生津止渴,升阳止泻。
莱菔子—消食除胀,降气化痰,止内痛。
玉米须—利尿消肿,清肝利胆。
淡竹叶—清热除烦,利尿,口舌生疮
鱼腥草—清热解毒,利尿消肿。
与现有技术相比,本发明的有益效果为:
(一)采用全鲵和鸡内金经现在最先进的酶解+膜过滤技术,这种技术分离出的复合蛋白多肽液具有可控的分子量,且品质好、活性高。
(二)本产品中的蛋白多肽能与进入机体内的有毒化合物、重金属扇子或致癌物质等相结合并促其排出体外,起到了中和解毒作用。
金属硫蛋白—金属硫蛋白是具有结合金属能力和高诱导特性的低分子量蛋白质。富含半胱氨酸的短肽,对多种重金属有高度亲和性并促其排出体外,而且具有很强的抗氧化活动。
(三)该复合制品中没有诸如单体肽、金属硫蛋白等任何一个单体物质在治疗痛风中有决定性的作用,而是大鲵和鸡内金蛋白多肽中已知的多肽、金属硫蛋白、硒元素和微量元素与多肽和中草药中现代科学未发现的某种物质相互协同完成的。
(四)该复合制品不仅对痛风有很好的治疗作用,而且对人体没有副作用,同时对人体免疫力低下,以及人体痛风结石、高尿酸及其它结石的化解等均有一定的治疗效果。
具体实施方式
下面结合具体实施方式对本发明的上述发明内容作进一步的详细描述。但不应将此理解为本发明上述主题的范围仅限于下述实施例。在不脱离本发明上述技术思想情况下,根据本领域普通技术知识和惯用手段,做出各种替换和变更,均应包括在本发明的范围内。
实施例1:
一种用于治疗痛风的复合制品(液剂)的制备方法,包括以下步骤:
1)大鲵蛋白多肽原液的制备。将活大鲵停食数天使其排空肠道,再宰杀去胆囊,得大鲵全体组织。将大鲵全体组织36kg和鸡内金5kg加纯净水36L进行蒸煮,蒸煮温度为120℃,压力为0.15MPa,蒸煮时间为0.5h。
向蒸煮后的料液中加入纯净水108L,当温度降至50℃,然后加入复合蛋白酶1.2kg(复合蛋白酶由中性蛋白酶0.4kg、木瓜蛋白酶0.5kg和风味蛋白酶0.3kg组成,风味蛋白酶由氨肽酶和羧肽酶以质量比3:1组成),然后将料液温度始终控制在50℃并保持5h,期间保持均速搅动,最后获得酶解液。
酶解液经转速为15000转/min的离心机离心获得离心液,离心液在经20000Da超滤膜过滤。最终获得分子量≤20000Da的蛋白多肽原液125L。
2)中草药原液的制备。
准备中草药原料当归3kg,枸杞4kg,葛根5kg,莱菔子5kg,淡竹叶2kg,玉米须2kg和鱼腥草0.5kg。
将上述中草药原料混合在一起加水浸泡1h,水与中草药原料的质量比为4:1,然后用旺火将其熬至沸腾,然后小火(40-50℃)再熬制1.5小时即得药液;
待熬制好的药液温度降至30℃左右时,用500目的尼龙筛布过滤获得药液,然后在将药液放入浴锅内浓缩,浓缩至50L即得中草药原液。
3)将前述得到的大鲵蛋白多肽原液125L,中草药原液50L,再和1400g柠檬酸、260g黄原胶、62g三氯蔗糖和75g山梨酸钾一起进行胶体磨混合;混合液升温灭菌,当温度升至98—100℃时保持25min,然后将温度降至60℃进行混合液灌装,灌装剂量每支10mL至60mL,包装瓶以棕色为好。
4)将上述灌装好的产品进行巴氏灭菌,然后烘干,然后贴标;
5)将上述贴标后的产品进行卫生检测,合格后,装盒装箱入库。
本液体制品中蛋白质含量≥2.11g/100mL,脂肪≥0.1g/100mL,肽≥1.9g/100mL,有微弱的大鲵腥味。
按照实施例1中的制备方法进行用于治疗痛风复合制品的制备,仅改变原料的添加量,分别为实施例2至实施例5,然后将实施例1至实施例5中的原料列表如下:
实验1:
将按照实施例1-5中配方制备得到的用于治疗痛风复合制品与采用秋水碱片(现常用做痛风治疗的药物)进行药效测定,选取患有痛风疾病的患者60名(通过专业医生根据发作频率、患病时间以及并发脏器功能损害程度判定患者轻重等级相同),将其分为6组,每组10人,并使得6组患者分别服用实施例1-5服用提供的痛风药方制成的药剂(每组患者服用的药剂相同,且服用的药剂量相同)和秋水碱片(按照推荐服用剂量进行服用),服用药剂期间,饮食均保持清淡,记录以下数据:
a、觉得有效果的人数(人);
b、尿酸下降的人数(人);
c、痛风结节变小的人数(人);
d、出现副作用的人数(人);
e、出现副作用的人,出现副作用的平均时间(天)。
a | b | c | d | e | |
实施例1 | 50 | 15 | 10 | 0 | 0 |
实施例2 | 50 | 5 | 2 | 0 | 0 |
实施例3 | 3 | 0 | 0 | 0 | 0 |
实施例4 | 2 | 0 | 0 | 0 | 0 |
实施例5 | 50 | 16 | 9 | 0 | 0 |
对比例1 | 10 | 7 | 0 | 10 | 7 |
通过实验证明,实施例1-实施例5中制备得到的用于治疗痛风复合制品,对于患者的治愈效果好、治愈时间短、过程中未出现副作用;实施例1和实施例5效果最佳。
案例(均服用采用实施例1中制备得到的用于治疗痛风复合制品):
袁某:男,生于1969年,今年50岁,工作于保险行业。患痛风6年,左脚踝关节外侧痛风结石形成已近两年,结石大小0.5cm。每天服用本发明液体制品20mL,早晚饭前各服用10mL。经过一个月的治疗,脚踝关节外侧痛风结石完全消失。
俸某:男,生于1978年,今年41岁,工作于农村农业局。患痛风10年。最近两年痛风每周发作一至两次,双膝关节疼痛伴关节腔积液,一年抽积液4至5次。右脚踝关节外侧、左肘关节、左手指关节已有痛风结石,左手已不能正常握拳。第一、第二个月,每天服用冷冻或低温喷雾干燥获得的复合原粉0.734g,将该复合原粉混入40g燕麦粉,早晚饭前各食用20g,第三至第五个月,每天早晚各食用40g,不在食用其他食品。经5个月治疗,各关节的痛风结石逐步消失,在这5个月中未抽过一次关节腔积液,手掌已能正常握拳。
徐某:男,生于1973年,今年46岁,工作于建筑行业。患痛风11年,肘关节、腕关节、脚踝关节外侧均有圆形凸起不规则结节,痛风结石形成已两年,痛风结石小的0.1cm、大的约2cm,尿酸高达640。第一、第二个月每天服用本发明液体制品20mL,早晚饭前各服用10mL,第三至第六个月每天服用本发明液体制品40mL,早晚饭前各服用20mL。经6个月治疗,各关节的痛风结石消失,尿酸恢复至310。
从本申请可以看出,复合蛋白多肽在中草药的协同下,将人体多余自由基和重金属等有害物质化解螯合排除体外。整个过程就是全面疏理调节人体的经络系统,人体整个经络系统一旦被梳理通畅,人体代谢紊乱将恢复正常,尿酸将顺畅通过各正常经络系统而无法结晶沉积,已有的痛风结石将逐步消减排出体外。最终关节功能及尿酸将逐步恢复正常,痛风逐步消失。
由于本申请中用于治疗痛风的复合制品能够从根本上解决药品及手术治疗痛风给人体带来的诸如肝、肾及经络损伤等弊端,达到标本兼治。原理为:
①大鲵和鸡内金蛋白多肽复合制品患者服用后,该复合制品中的小分子肽迅速进入人体经络系统,将系统中多余的自由基清除。
②大鲵和鸡内金蛋白多肽复合制品患者服用后,该复合制品中的“金属硫蛋白”与人体中的重金属螯合将其排除体外。
③该复合制品中各成分在一起可起到协作增效的技术效果,共同完成对人体整个系统梳理,使系统畅通,代谢紊乱恢复正常。人体系统的代谢紊乱一旦恢复正常,其尿液中含有的晶体物质和非晶体物质将在正常系统中顺畅通过无法沉积,已形成的痛风结石也将缓慢消化排除体外,给患者带来福音。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。本领域的技术人员来说,在不脱离本发明技术方案的前提下,还可以作出若干变形和改进,这些也应该视为本发明的保护范围,这些都不会影响本专利实施的效果和专利的实用性。
Claims (7)
1.一种用于治疗痛风的复合制品,其特征在于:该复合制品中含有大鲵多肽和鸡内金酶解物。
2.一种用于治疗痛风的复合制品,其特征在于:该复合制品包括复合蛋白多肽和中药组合物;所述的复合蛋白多肽以大鲵全体组织、鸡内金和复合蛋白酶为主要原料制备而成;中药组合物由当归、枸杞、葛根、莱菔子、淡竹叶、玉米须和鱼腥草按比例制备而成;复合蛋白多肽和中药组合物的质量比为50-180:20-100。
3.如权利要求2所述用于治疗痛风的复合制品,其特征在于所述中药组合物中各原料的重量份为:当归1-9份,枸杞1-10份,葛根1-12份,莱菔子1-15份,淡竹叶1-6份,玉米须1-10份,鱼腥草1-3份。
4.如权利要求2所述用于治疗痛风的复合制品,其特征在于:大鲵全体组织、鸡内金和复合蛋白酶的质量比为1-7:1:1-2。
5.如权利要求2至权利要求4中任意一项权利要求所述用于治疗痛风的复合制品的制备方法,其特征在于包括以下步骤:
⑴、将大鲵全体组织与鸡内金按比例混合,再加入复合蛋白酶经酶解分离获得的复合蛋白多肽原液备用;
⑵、按比例称取当归、枸杞、葛根、莱菔子、鱼腥草、淡竹叶和玉米须,加水进行熬制,再将熬制的药液用500目尼龙筛布过滤,最后浓缩成中草药原液备用;
⑶、将前述步骤制备得到的复合蛋白多肽原液和中草药原液混合,再向混合液中加入柠檬酸、黄原胶、三氯蔗糖和山梨酸钾进行胶体磨混合即得。
6.如权利要求5所述用于治疗痛风的复合制品的制备方法,其特征在于步骤(1)的具体步骤为:
(1.1)将大鲵全体组织36kg和鸡内金5kg加纯净水36L进行蒸煮,蒸煮温度为120℃,压力为0.15MPa,蒸煮时间为0.5h;
(1.2)向蒸煮后的料液中加入纯净水108L,当温度降至50℃,然后加入复合蛋白酶1.2kg,然后将料液温度始终控制在50℃并保持5-6h,期间保持均速搅动,最后获得酶解液;
(1.3)将步骤(1.2)中得到的酶解液进行离心分离,离心机的转速为15000转/min;得到的离心液经20000Da超滤膜过滤,得分子量≤20000Da的蛋白多肽原液125L。
7.如权利要求5所述用于治疗痛风的复合制品的制备方法,其特征在于步骤(2)的具体步骤为:
(2.1)将称取到的中草药原料当归5kg、枸杞5kg、葛根6kg、莱菔子8kg、鱼腥草2kg、淡竹叶3kg和玉米须5kg混合在一起后加水浸泡1h,水与中草药原料的质量比为4:1,然后用旺火将药液熬至沸腾,然后小火再熬制1.5h即可;
(2.2)将熬制好的药液温度降至30℃,用500目尼龙筛布过滤获得药液,然后在将药液放入浴锅内浓缩得中药组合物原液50kg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910641415.XA CN110354245A (zh) | 2019-07-16 | 2019-07-16 | 一种用于治疗痛风的复合制品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910641415.XA CN110354245A (zh) | 2019-07-16 | 2019-07-16 | 一种用于治疗痛风的复合制品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110354245A true CN110354245A (zh) | 2019-10-22 |
Family
ID=68219666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910641415.XA Pending CN110354245A (zh) | 2019-07-16 | 2019-07-16 | 一种用于治疗痛风的复合制品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110354245A (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178217A (zh) * | 2011-03-04 | 2011-09-14 | 汉中天成生物工程有限公司 | 含魔芋粉的混合物及其制备方法 |
CN104041881A (zh) * | 2014-06-16 | 2014-09-17 | 四川溪源水产养殖有限公司 | 一种大鲵多肽饮品及其制备方法 |
CN106942578A (zh) * | 2017-03-08 | 2017-07-14 | 杨涵 | 一种控制嘌呤摄入及促进尿酸排泄的天然膳食 |
CN107303386A (zh) * | 2016-04-25 | 2017-10-31 | 高安友 | 一种用于治疗白细胞低下的口服液的制备方法 |
CN107412612A (zh) * | 2017-04-19 | 2017-12-01 | 广西大学 | 一种保健降尿酸代用茶及其制备方法 |
CN107496762A (zh) * | 2017-09-20 | 2017-12-22 | 贵阳健圣堂药材有限公司 | 一种降低高尿酸预防改善痛风的保健茶及其制备方法和应用 |
CN108042786A (zh) * | 2017-12-25 | 2018-05-18 | 高安友 | 一种用于增加骨密度的大鲵多肽复合口服饮品 |
CN108815304A (zh) * | 2018-09-10 | 2018-11-16 | 张家界金鲵生物工程股份有限公司 | 一种增强免疫力的中草药剂及其制备方法 |
CN108938961A (zh) * | 2018-10-09 | 2018-12-07 | 乐清市足资初生物科技有限公司 | 一种治疗痛风的中药茶及其制备方法 |
CN109400753A (zh) * | 2017-08-15 | 2019-03-01 | 清华大学 | 大鲵软骨制剂 |
CN109876094A (zh) * | 2017-11-27 | 2019-06-14 | 随州市万松堂康汇保健品有限公司 | 一种针对结石人群的复合固体饮料及其制备方法 |
-
2019
- 2019-07-16 CN CN201910641415.XA patent/CN110354245A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178217A (zh) * | 2011-03-04 | 2011-09-14 | 汉中天成生物工程有限公司 | 含魔芋粉的混合物及其制备方法 |
CN104041881A (zh) * | 2014-06-16 | 2014-09-17 | 四川溪源水产养殖有限公司 | 一种大鲵多肽饮品及其制备方法 |
CN107303386A (zh) * | 2016-04-25 | 2017-10-31 | 高安友 | 一种用于治疗白细胞低下的口服液的制备方法 |
CN106942578A (zh) * | 2017-03-08 | 2017-07-14 | 杨涵 | 一种控制嘌呤摄入及促进尿酸排泄的天然膳食 |
CN107412612A (zh) * | 2017-04-19 | 2017-12-01 | 广西大学 | 一种保健降尿酸代用茶及其制备方法 |
CN109400753A (zh) * | 2017-08-15 | 2019-03-01 | 清华大学 | 大鲵软骨制剂 |
CN107496762A (zh) * | 2017-09-20 | 2017-12-22 | 贵阳健圣堂药材有限公司 | 一种降低高尿酸预防改善痛风的保健茶及其制备方法和应用 |
CN109876094A (zh) * | 2017-11-27 | 2019-06-14 | 随州市万松堂康汇保健品有限公司 | 一种针对结石人群的复合固体饮料及其制备方法 |
CN108042786A (zh) * | 2017-12-25 | 2018-05-18 | 高安友 | 一种用于增加骨密度的大鲵多肽复合口服饮品 |
CN108815304A (zh) * | 2018-09-10 | 2018-11-16 | 张家界金鲵生物工程股份有限公司 | 一种增强免疫力的中草药剂及其制备方法 |
CN108938961A (zh) * | 2018-10-09 | 2018-12-07 | 乐清市足资初生物科技有限公司 | 一种治疗痛风的中药茶及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11571452B2 (en) | Method of treating a skin wound with a liquid-state topical pharmaceutical composition | |
Posmontier | The medicinal qualities of Moringa oleifera | |
CN107753801A (zh) | 降尿酸、降嘌呤治疗痛风的药物组合物及其制备方法 | |
RU2419449C1 (ru) | Средство для лечения больных лекарственным гепатитом | |
CN102274380B (zh) | 治疗烧、烫伤的外用药 | |
KR20180039813A (ko) | 생약 추출물을 포함하는 가축의 질병 예방 또는 면역력 강화를 위한 음용수 제조 방법 | |
CN110354245A (zh) | 一种用于治疗痛风的复合制品及其制备方法 | |
CN102240310A (zh) | 一种降血糖组合物及其制备方法 | |
CN106975036A (zh) | 一种复方降酸茶及其制备方法 | |
KR20190044823A (ko) | 만성 근골격계 질환 개선 조성물 | |
CN100502905C (zh) | 一种抗菌生肌的中药制剂 | |
CN109806313A (zh) | 一种治疗痛风的外用药 | |
CN104547989B (zh) | 一种用于治疗脊椎病的藏药膏剂及其使用方法 | |
CN108066518A (zh) | 一种犬用中药浴液组合物及其制备方法 | |
CN108524734A (zh) | 一种烫伤药膏及其制备方法 | |
CN114712482B (zh) | 一种含虾青素的洁阴抑菌凝胶及其制备方法 | |
CN109925426A (zh) | 一种可以治疗痔疮的中药熏蒸剂 | |
CN107050303A (zh) | 一种用于治疗糖尿病烂足的中药组合物 | |
CN105902842A (zh) | 一种新型治疗眼睛疲劳的护眼膏药及其制备方法 | |
CN105288131A (zh) | 一种治疗肾结核的中药汤剂及其制备方法 | |
CN109602835A (zh) | 一种具有促进皮肤愈合功效的中药配方及熬制方法 | |
CN108671098A (zh) | 一种化石丹及其制备方法 | |
TWI535447B (zh) | 抑制腫瘤生長之草藥萃取物 | |
CN109303818A (zh) | 一种治疗类风湿的药酒的制备方法 | |
CN104706744B (zh) | 一种中药组合物及其应用与制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191022 |
|
RJ01 | Rejection of invention patent application after publication |